Trial Profile

A Double-Blind Phase 3 Extension Trial Assessing the Long Term Safety and Efficacy of Glepaglutide in Patients With Short Bowel Syndrome (SBS)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 11 Sep 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Glepaglutide (Primary)
Indications Short bowel syndrome
Focus Adverse reactions; Registrational; Therapeutic Use
Acronyms EASE SBS 2; EASE-2
Sponsors Zealand Pharma

Most Recent Events

08 Sep 2026 Status changed from active, no longer recruiting to completed.
30 Jan 2026 Planned End Date changed from 31 Oct 2026 to 1 Apr 2026.
30 Jan 2026 Planned primary completion date changed from 31 Oct 2026 to 1 Apr 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com